Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.79 |
| ▸ | MEN1 | O00255 | 3/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.72 |
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.64 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.64 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.64 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.64 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.64 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 4/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9312746 | 0.89 | KMT2A (1.00) | KMT2AMEN1LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL13437936 | 0.87 | KMT2A (0.82) | KMT2AMEN1LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL25737020 | 0.86 | MEN1 (0.74) | KMT2AMEN1LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL13752250 | 0.85 | HDAC3 (0.64) | KMT2AMEN1LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL4228749 | 0.84 | SMN1; SMN2 (1.00) | KMT2AMEN1LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL295936 | 0.84 | KMT2A (0.83) | KMT2AMEN1LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL15966067 | 0.84 | L3MBTL1 (0.56) | KMT2AMEN1LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL16303386 | 0.84 | KMT2A (0.77) | KMT2AMEN1LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL6360691 | 0.84 | KMT2A (0.77) | KMT2AMEN1LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL12956151 | 0.84 | LMNA (0.60) | KMT2AMEN1LMNAL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169246-B2 | Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2015-10-27 | — | — | US | disclosed |
| EP-2213650-B1 | SUBSTITUTED DIPHENYLAMINES AS INHIBITORS OF REVERSE TRANSCRIPTASE, PROCESS OF PREPARING THEM AND USE THEREOF | INST PHARM & TOXICOLOGY AMMS (CN) | 2015-08-12 | — | — | EP | disclosed |
| US-20130079337-A1 | PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-03-28 | — | — | US | disclosed |
| US-8309602-B2 | Multi-substituted diarylanilines as non-nucleoside HIV reverse transcriptase inhibitors, and preparation and use thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY (CN) | 2012-11-13 | — | — | US | disclosed |
| US-20100292324-A1 | Multi-Substituted Diarylanilines as Non-Nucleoside HIV Reverse Transcriptase Inhibitors, and Preparation and Use Thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2010-11-18 | — | — | US | disclosed |
| EP-2213650-A1 | SUBSTITUTED DIPHENYLAMINES AS INHIBITORS OF REVERSE TRANSCRIPTASE, PROCESS OF PREPARING THEM AND USE THEREOF | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China (CN) | 2010-08-04 | — | — | EP | disclosed |
| US-20080207718-A1 | Use of Fused Imidazole Derivatives to Mediate Ccr3 Related Conditions | BECKWITH ROHAN | 2008-08-28 | — | — | US | disclosed |
| US-20080207718-A1 | Use of Fused Imidazole Derivatives to Mediate Ccr3 Related Conditions | BECKWITH ROHAN | 2008-08-28 | — | — | US | disclosed |
| WO-2007025751-A1 | USE OF FUSED IMIDAZOLE DERIVATIVES TO MEDIATE CCR3 RELATED CONDITIONS | NOVARTIS AG (CH) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292324-A1 | Multi-Substituted Diarylanilines as Non-Nucleoside HIV Reverse Transcriptase Inhibitors, and Preparation and Use Thereof | PNP, POLRMT, QTRT1 | KMT2A 418/4885MEN1 3688/4885LMNA 1215/4885 |
| US-20130079337-A1 | PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CYP11B2, COQ8A, CYP1A2 | KMT2A 3452/4885MEN1 1323/4885LMNA 2087/4885 |
| US-20080207718-A1 | Use of Fused Imidazole Derivatives to Mediate Ccr3 Related Conditions | CCR3, CCR1, CCR4 | KMT2A 3492/4885MEN1 3895/4885LMNA 3847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.